Cagrilintide + Semaglutide Blend

What is Cagrilintide + Semaglutide Blend?

The Cagrilintide + Semaglutide Blend is a research co-formulation of two synthetic peptides in a single lyophilised vial: cagrilintide, a long-acting acylated analogue of the 37-amino-acid hormone amylin that activates amylin and calcitonin receptors, and semaglutide, a 31-amino-acid GLP-1 receptor agonist. Each vial contains the two peptides in equal mass, either 2.5mg + 2.5mg (5mg total) or 5mg + 5mg (10mg total).

This pairing mirrors the combination being studied in late-stage clinical trials, where an amylin analogue and a GLP-1 analogue are given together because they act on separate satiety pathways. GenoPept supplies the Cagrilintide + Semaglutide Blend as a research product for UK laboratories. It is for in-vitro research use only and is not a medicine.

Cagrilintide + Semaglutide Blend research applications

The rationale for co-investigating cagrilintide and semaglutide is that amylin and GLP-1 receptors engage complementary circuits. The preclinical research areas below are typical.

Additive satiety signalling

Research explores whether combined amylin and GLP-1 receptor activation reduces food intake and body weight more than either peptide alone in diet-induced obesity models, with the blend providing a convenient fixed-ratio starting point.

Receptor cross-talk studies

The Cagrilintide + Semaglutide Blend is used in cell-based assays to examine whether co-activation of calcitonin-family and GLP-1 receptors alters cAMP signalling, receptor trafficking or downstream gene expression.

Gastric emptying and glucose handling

Both amylin and GLP-1 slow gastric emptying and suppress glucagon, so the blend has been investigated in animal models to characterise combined effects on post-prandial glucose and glucagon.

Comparative incretin combination research

The blend allows laboratories to benchmark an amylin plus GLP-1 strategy against dual and triple incretin agonists such as tirzepatide and retatrutide.

Mechanism of action (preclinical)

Cagrilintide activates amylin receptors (calcitonin receptor plus RAMP heterodimers) in the area postrema and hypothalamus, reducing meal size, slowing gastric emptying and suppressing glucagon secretion. Semaglutide activates the GLP-1 receptor on beta cells, neurons and other tissues, raising cAMP to enhance glucose-dependent insulin release and reduce food intake through hypothalamic and brainstem circuits.

Because the two receptors and their neural targets are distinct, preclinical models report that the combination produces greater effects on energy balance than either component alone. Both peptides carry fatty diacid side chains that bind albumin, giving them comparable once-weekly pharmacokinetic profiles in published studies.

Cagrilintide + Semaglutide Blend product specifications

Available sizes

Cagrilintide + Semaglutide Blend is available in the following vial sizes:

• 5mg (2.5mg + 2.5mg) vial
• 10mg (5mg + 5mg) vial

Laboratories that need larger quantities can order in bulk boxes of 10 vials, which save 20–50% against single-vial pricing. Retail baskets also receive automatic discounts at £300, £500 and £1,000, and delivery is free on UK orders of £200 or more.

Reconstitution, handling and storage (laboratory)

Unopened Cagrilintide + Semaglutide Blend vials should be stored at −20 °C for long-term storage, or at 2–8 °C for short periods, and protected from light. Allow the vial to reach room temperature before opening to avoid condensation on the lyophilised cake.

To reconstitute for in-vitro work, add bacteriostatic water or another sterile diluent slowly down the inside wall of the vial, then swirl gently until the powder dissolves. Do not shake, as agitation can damage large acylated peptides. Reconstituted solution should be kept at 2–8 °C and used within the period specified in the laboratory’s own protocol. See our guides on how to reconstitute research peptides and how to store research peptides for step-by-step handling notes.

Quality assurance and Certificate of Analysis

Every batch of Cagrilintide + Semaglutide Blend is tested by an independent third-party laboratory (Puralytix, ISO/IEC 17025 accredited) using HPLC for purity and LC-MS for identity confirmation. Results are published in a batch-specific Certificate of Analysis (COA), and each vial is labelled with its lot number and expiry date so the paperwork can be matched to the product on the bench.

Use the “View Certificate of Analysis” button on this page to open the current batch COA, or browse the full COA library. Our article on what a Certificate of Analysis shows explains how to read the chromatogram and mass spectrum.

Related research compounds

• Cagrilintide: the amylin analogue component, available on its own for single-agent controls.
• Semaglutide: the GLP-1 receptor agonist component in single-peptide vials.
• Retatrutide + Cagrilintide Blend: pairs the amylin analogue with a triple incretin agonist instead.
• Tirzepatide: a dual GIP/GLP-1 receptor agonist for benchmarking combination strategies.

Cagrilintide + Semaglutide Blend frequently asked questions

What is the Cagrilintide + Semaglutide Blend used for in research?

The Cagrilintide + Semaglutide Blend is used in laboratories to study combined amylin and GLP-1 receptor signalling. Preclinical research applies it to satiety and body-weight models, receptor cross-talk assays, gastric emptying and glucose handling studies, and comparisons against dual or triple incretin agonists. It is supplied for in-vitro and animal-model research only, never for human use.

How is the blend supplied and what is in each vial?

Each vial contains cagrilintide and semaglutide in equal mass as lyophilised powder: the 5mg vial holds 2.5mg of each peptide and the 10mg vial holds 5mg of each. Vials are sealed, sterile glass with a black cap and are labelled with lot and expiry. Purity of at least 99% and identity are confirmed by independent HPLC and LC-MS testing with a Certificate of Analysis.

How should the Cagrilintide + Semaglutide Blend be stored?

Store unopened vials at minus 20 degrees Celsius for long-term storage, or at 2 to 8 degrees Celsius for short periods, protected from light. After reconstitution with bacteriostatic water or sterile diluent, keep the solution at 2 to 8 degrees Celsius and use it within the period specified in your laboratory protocol, as both peptides are large acylated molecules.

Is the Cagrilintide + Semaglutide Blend for human use?

No. The Cagrilintide + Semaglutide Blend supplied by GenoPept is strictly for in-vitro laboratory research. It is not a medicine, is not prepared for administration, and must not be used for human or veterinary purposes, diagnosis or treatment. Purchasers are responsible for complying with UK research use only requirements and institutional policies.

Why combine cagrilintide with semaglutide rather than use either alone?

Cagrilintide acts on amylin and calcitonin receptors while semaglutide acts on the GLP-1 receptor, so the two peptides engage different satiety and metabolic pathways. Research explores whether this produces additive effects in preclinical models. A single-vial blend gives laboratories a fixed 1:1 mass ratio and removes the need to weigh and combine two separate peptides.

Research use only. Cagrilintide + Semaglutide Blend is supplied by GenoPept strictly for in-vitro laboratory research. It is not a medicine, is not for human or veterinary use, and is not intended for diagnostic or therapeutic purposes. Read our research use only policy and UK legal guide before ordering.